Abstract 439P
Background
To investigate the clinical efficacy, preservation of laryngeal function, and safety differences between PD-1 inhibitors combined with chemotherapy and targeted therapy combined with chemotherapy in LA HPSCC patients.
Methods
Retrospective analysis of patients with LA HPSCC treated at the Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University from October 2020 to March 2024. A total of 110 eligible patients were included according to the inclusion criteria, including 56 in the Pembrolizumab combined with TP regimen group (Group A) and 54 in the Nimotuzumab combined with TP regimen group (Group B). Relevant clinical data were collected. The clinical efficacy, preservation of laryngeal function, CR rate, pCR rate, MPR and treatment- related adverse events (TRAEs), etc. of the two groups of patients were analyzed and compared.
Results
In both groups A and B, the ORR and DCR were similar with no significant difference, but the pCR rate in Group A was much higher than that in Group B (37.5% vs 7.4% ,p<0.001). The rate of primary tumor downstaging in group A was much higher than that in group B (76.8% vs 38.9%, p<0.0001). The median follow-up time was 10 months, and the 1y-OS rate in group A was 95.7%, compared to 87.0% in group B (p=0.106, HR=0.34;95%CI：0.114-1.013). The 1y-PFS rate was 89.4% in group A and 85.2% in group B (p=0.399, HR=0.675; 95%CI:0.275-1.659). The larynx function preservation rate of Group A and B were 85.7% and 66.7% (p=0.019). The safety analysis indicated that there were no deaths due to TRAEs in either group, and there was no significant difference in the incidence of grade 3-4 TRAEs between the two groups (p=0.77). The main TRAEs in Group A were metabolism and nutrition disorders (52/56,92.9%), while in Group B they were blood and lymphatic system disorders (40/54,74.1%).
Conclusions
This retrospective analysis showed that PD-1 inhibitors combined with chemotherapy showed better short-term efficacy compared to targeted therapy. Additionally, a trend toward improved long-term survival was observed. Both groups indicated that neoadjuvant therapy is safe and manageable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.